These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24854110)

  • 1. Rosuvastatin inhibits TIMP-2 and promotes myocardial angiogenesis.
    Siddiqui AJ; Gustafsson T; Sylven C; Crisby M
    Pharmacology; 2014; 93(3-4):178-84. PubMed ID: 24854110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.
    Solini A; Rossi C; Santini E; Madec S; Salvati A; Ferrannini E
    J Hypertens; 2011 Oct; 29(10):1930-9. PubMed ID: 21881526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
    Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
    Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet.
    Famer D; Crisby M
    Neurosci Lett; 2007 May; 419(1):68-73. PubMed ID: 17433542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yellow wine polyphenolic compounds inhibit matrix metalloproteinase-2, -9 expression and improve atherosclerotic plaque in LDL-receptor-knockout mice.
    Zhai X; Chi J; Tang W; Ji Z; Zhao F; Jiang C; Lv H; Guo H
    J Pharmacol Sci; 2014; 125(2):132-41. PubMed ID: 24859779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
    Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
    Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
    Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combined treatment with rosuvastatin and protein kinase Cβ2 inhibitor on angiogenesis following myocardial infarction in diabetic rats.
    Huang D; Wang FB; Guo M; Li S; Yan ML; Yu T; Wei M; Li JB
    Int J Mol Med; 2015 Mar; 35(3):829-38. PubMed ID: 25524396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
    Chen J; Li D; Schaefer RF; Mehta JL
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):446-52. PubMed ID: 15454852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The complementary effects of atorvastatin and exercise treatment on the composition and stability of the atherosclerotic plaques in ApoE knockout mice.
    Moustardas P; Kadoglou NP; Katsimpoulas M; Kapelouzou A; Kostomitsopoulos N; Karayannacos PE; Kostakis A; Liapis CD
    PLoS One; 2014; 9(9):e108240. PubMed ID: 25264981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rosuvastatin on the production and activation of matrix metalloproteinase-2 and migration of cultured rat vascular smooth muscle cells induced by homocysteine.
    Shi YF; Chi JF; Tang WL; Xu FK; Liu LB; Ji Z; Lv HT; Guo HY
    J Zhejiang Univ Sci B; 2013 Aug; 14(8):696-704. PubMed ID: 23897788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acipimox attenuates atherosclerosis and enhances plaque stability in ApoE-deficient mice fed a palmitate-rich diet.
    Jin F; Jiang S; Yang D; Zhang X; Yang Y; Zhang Y; Li K; Yang Y; Ma S
    Biochem Biophys Res Commun; 2012 Nov; 428(1):86-92. PubMed ID: 23058919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
    Schäfer K; Kaiser K; Konstantinides S
    Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.
    Monetti M; Canavesi M; Camera M; Parente R; Paoletti R; Tremoli E; Corsini A; Bellosta S
    Pharmacol Res; 2007 May; 55(5):441-9. PubMed ID: 17350858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF.
    Zaitone SA; Abo-Gresha NM
    Eur J Pharmacol; 2012 Sep; 691(1-3):134-42. PubMed ID: 22732653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice.
    Schroeter MR; Humboldt T; Schäfer K; Konstantinides S
    Atherosclerosis; 2009 Jul; 205(1):63-73. PubMed ID: 19111832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent effect of rosuvastatin in the regulation of metalloproteinase expression.
    Sapienza P; Borrelli V; Sterpetti AV; Dinicola S; Tartaglia E; di Marzo L
    Ann Vasc Surg; 2011 Aug; 25(6):823-9. PubMed ID: 21620672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice.
    Delsing DJ; Post SM; Groenendijk M; Solaas K; van der Boom H; van Duyvenvoorde W; de Wit EC; Bloks VW; Kuipers F; Havekes LM; Princen HM
    J Cardiovasc Pharmacol; 2005 Jan; 45(1):53-60. PubMed ID: 15613980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
    Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
    Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung.
    Chang CC; Wang SS; Hsieh HG; Lee WS; Chuang CL; Lin HC; Lee FY; Lee SD; Huang HC
    Clin Sci (Lond); 2015 Sep; 129(6):449-60. PubMed ID: 25940601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.